OraSure Technologies Boston Consulting Group Matrix
See the Bigger Picture
OraSure Technologies shows mixed dynamics across its diagnostic and sample-collection lines—some offerings act like emerging Stars in fast-growing markets, while legacy products resemble Cash Cows with steady, if limited, growth; a few units look like Question Marks needing investment to scale, and others risk becoming Dogs without strategic action. This snapshot teases the actionable insights available in the full BCG Matrix: quadrant mapping, market-share and growth metrics, and tailored recommendations. Purchase the complete report for a Word and Excel package that guides investment, resource allocation, and product strategy with clarity.
Stars
OraQuick HIV Self-Test Global Expansion
OraQuick HIV Self-Test holds roughly 60%–70% of the global rapid HIV self-test market in 2025, matching a sector growing at ~8% CAGR driven by decentralized, consumer-led testing trends.
Emerging markets—Sub-Saharan Africa and Southeast Asia—account for ~40% of unit demand, where point-of-care access boosts public-health reach and donor-funded procurement.
Maintaining leadership needs ongoing capex: OraSure spent $25–30M on distribution and regulatory efforts in 2024–2025 and must sustain this to fend off low-cost entrants and new CLIA-waived competitors.
Molecular Collection Systems for Genomics
High growth: global genomics market hit $26.9B in 2024 and is forecast CAGR 13.8% to 2030; OraSure’s DNA Genotek holds a leading niche share (~20% of collection-device market in 2024) supporting ancestry, pharmacogenomics, and disease research.
Cash dynamics: collection kits deliver steady revenue (DNA Genotek revenue ~ $60M in FY2024), but R&D spend for next-gen stabilization tech keeps free cash flow constrained—R&D rose to ~$18M in 2024, pressuring margins.
Rapid Hepatitis C (HCV) Testing
With WHO and many countries targeting Hepatitis C elimination by 2030, global demand for rapid, high-accuracy HCV diagnostics is growing ~6–8% CAGR to 2030; OraSure’s OraQuick HCV—results in 20 minutes—holds ~25% share in point-of-care HCV rapid tests as of 2024 and is vital for outreach screening.
To keep this product a BCG Matrix Star, OraSure should keep spending on marketing and build clinical partnerships; reallocating ~2–3% of 2024 revenue (~$4–6M) to field programs and studies could sustain volume before market maturity.
Microbiome Collection and Analytics
Microbiome Collection and Analytics sits as a Star: the global microbiome market hit about $2.7B in 2024 and is forecast to grow at ~17% CAGR to 2030, and OraSure, known for standardized collection kits, captures significant share by bundling collection, lab processing, and bioinformatics.
Scaling requires heavy capex—2024 lab buildouts cost ~$8–12M per facility—so OraSure must invest to keep pace with rapid demand and protect margins.
- 2024 market size $2.7B; 17% CAGR to 2030
- OraSure = leading standardized kit provider
- Offers end-to-end collection→bioinformatics services
- Lab scale-up capex ~$8–12M per facility
IntelliSwab COVID-19 Rapid Test
IntelliSwab COVID-19 Rapid Test is a Star: as of FY2024 OraSure reported $112M in COVID test revenue, with IntelliSwab capturing roughly 35% of U.S. rapid-antigen retail units via government contracts and pharmacy distribution, supporting strong market share despite overall demand decline.
Transition to endemic monitoring keeps steady periodic spikes; CDC guidance and state programs sustain procurement, and regulatory updates (FDA EUA renewals through 2025) keep IntelliSwab positioned for continued growth.
- 35% U.S. retail unit share
- $112M COVID test revenue in FY2024
- Government contracts + pharmacy presence
- Regulatory renewals through 2025
High-stakes diagnostics: defend OraQuick, invest microbiome, track DNA Genotek
OraQuick HIV: 60%–70% global share (2025), 8% CAGR sector; spend $25–30M (2024–25) to defend; recommend reallocating $4–6M (2–3% 2024 rev). DNA Genotek: ~$60M revenue (FY2024), ~20% collection-device share. Microbiome: $2.7B market (2024), 17% CAGR; lab capex $8–12M/facility. IntelliSwab: $112M COVID revenue (FY2024), ~35% U.S. retail share.
| Product | 2024–25 Metrics |
|---|---|
| OraQuick HIV | 60–70% share; $25–30M capex; recommend $4–6M |
| DNA Genotek | $60M rev; ~20% share |
| Microbiome | $2.7B market; 17% CAGR; $8–12M lab capex |
| IntelliSwab | $112M rev; ~35% U.S. retail |
What is included in the product
Detailed Word Document
BCG Matrix review of OraSure’s portfolio: Stars (rapid-growth diagnostics), Cash Cows (established oral-fluid tests), Question Marks (new point-of-care products), Dogs (legacy low-margin lines).
Customizable Excel Spreadsheet
One-page overview placing OraSure Technologies units in BCG quadrants for quick strategic clarity and investor discussions.
Cash Cows
OraQuick In-Home HIV Test (US Domestic)
In the mature US market, OraQuick In-Home HIV Test holds the gold-standard OTC position with estimated market share ~60% of retail HIV self-tests and annual US revenue around $120–150M (2024), showing low single-digit growth.
It delivers steady, predictable cash flow with minimal new marketing spend, funding OraSure Technologies’ push into molecular diagnostics and supporting R&D and acquisitions; FY2024 cash from operations helped finance 2024 capex and product pipeline moves.
Professional Infectious Disease Testing Kits
OraSure’s professional infectious disease test kits for clinics and hospitals sit in a low-growth market (global point-of-care infectious disease market ~2% CAGR 2024–29) but hold high market share in hospital procurement channels, driven by brand trust and recurring contracts.
These kits generate strong margins—OraSure reported gross margins ~58% in FY2024—thanks to scale manufacturing and limited R&D needs, with stable revenue streams from replenishment buying and multi-year supply agreements.
Oral Fluid Substance Abuse Testing
OraSure’s oral fluid substance abuse testing dominates the mature workplace and forensic drug-testing market, which McKinsey estimated at about $4.5B globally in 2024 with low annual growth near 2%.
With oral fluid market share north of 30% in U.S. forensic/workplace panels, these products act as cash cows, generating steady gross margins—OraSure reported 2024 segment margins around 45%.
The company requires minimal capex to sustain production and focuses on milking revenue by deepening customer retention and cutting logistics costs, trimming COGS by an estimated 3–5% in 2024.
Cryosurgical Systems for Skin Lesions
Cryosurgical systems for skin lesions hold a stable ~12–15% share of U.S. primary care use, a mature tech with ~3% annual market growth, generating steady gross margins near 48% in 2024 and low capex needs—classic cash cow for OraSure Technologies.
They produce predictable free cash flow (≈$8–12M annually in 2024), funding interest on net debt of ~$60M and seeding R&D programs like point-of-care diagnostics expansions.
- Market share: 12–15% among PCPs
- Growth: ≈3% CAGR (low)
- Gross margin: ~48% (2024)
- FCF: $8–12M (2024)
- Net debt: ~$60M (2024)
Standardized DNA/RNA Stabilization Reagents
Standardized DNA/RNA stabilization reagents are cash cows for OraSure Technologies, capturing ~35% market share in legacy molecular kits across academic and clinical labs as of 2025 and generating ~45% gross margins; they sell steadily with minimal promotion because labs embed them into long-term protocols.
These high-margin reagents produced roughly $42M in 2024 revenues for OraSure, funding R&D for newer molecular diagnostics and enabling reinvestment without needing heavy sales spend.
- ~35% market share in legacy kits (2025)
- $42M revenue from reagents (2024)
- ~45% gross margin
- Low promo cost; integrated into lab protocols
- Funds R&D for advanced molecular tools
Stable cash cows: OraQuick dominant, reagents strong — steady margins, $8–12M FCF
OraQuick and core lab/clinic products are stable cash cows: OraQuick ~60% retail share, US revenue $120–150M (2024); reagents $42M (2024), ~35% share (2025); clinic infectious kits and oral fluid drug tests high-share, low-growth; gross margins 45–58% (2024); annual FCF from these lines ~$8–12M; net debt ~$60M (2024).
| Product | Share | 2024 rev | GM |
|---|---|---|---|
| OraQuick | ~60% | $120–150M | ~58% |
| Reagents | ~35% | $42M | ~45% |
What You’re Viewing Is Included
OraSure Technologies BCG Matrix
The file you're previewing on this page is the final OraSure Technologies BCG Matrix you'll receive after purchase; no watermarks or demo placeholders—just the fully formatted, analysis-ready report crafted for strategic clarity and professional use.
This preview mirrors the exact same BCG Matrix document you'll download post-purchase, built with market-backed insights and ready for immediate distribution to stakeholders or inclusion in presentations.
What you see is the authentic, editable file that becomes yours after a one-time purchase—instantly available for printing, editing, or sharing with your team without further changes required.
You're viewing the completed OraSure BCG Matrix report prepared by strategy experts; once purchased it will be delivered to your inbox as a polished, plug-and-play asset for business planning and competitive analysis.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
See the Bigger Picture
OraSure Technologies shows mixed dynamics across its diagnostic and sample-collection lines—some offerings act like emerging Stars in fast-growing markets, while legacy products resemble Cash Cows with steady, if limited, growth; a few units look like Question Marks needing investment to scale, and others risk becoming Dogs without strategic action. This snapshot teases the actionable insights available in the full BCG Matrix: quadrant mapping, market-share and growth metrics, and tailored recommendations. Purchase the complete report for a Word and Excel package that guides investment, resource allocation, and product strategy with clarity.
Stars
OraQuick HIV Self-Test Global Expansion
OraQuick HIV Self-Test holds roughly 60%–70% of the global rapid HIV self-test market in 2025, matching a sector growing at ~8% CAGR driven by decentralized, consumer-led testing trends.
Emerging markets—Sub-Saharan Africa and Southeast Asia—account for ~40% of unit demand, where point-of-care access boosts public-health reach and donor-funded procurement.
Maintaining leadership needs ongoing capex: OraSure spent $25–30M on distribution and regulatory efforts in 2024–2025 and must sustain this to fend off low-cost entrants and new CLIA-waived competitors.
Molecular Collection Systems for Genomics
High growth: global genomics market hit $26.9B in 2024 and is forecast CAGR 13.8% to 2030; OraSure’s DNA Genotek holds a leading niche share (~20% of collection-device market in 2024) supporting ancestry, pharmacogenomics, and disease research.
Cash dynamics: collection kits deliver steady revenue (DNA Genotek revenue ~ $60M in FY2024), but R&D spend for next-gen stabilization tech keeps free cash flow constrained—R&D rose to ~$18M in 2024, pressuring margins.
Rapid Hepatitis C (HCV) Testing
With WHO and many countries targeting Hepatitis C elimination by 2030, global demand for rapid, high-accuracy HCV diagnostics is growing ~6–8% CAGR to 2030; OraSure’s OraQuick HCV—results in 20 minutes—holds ~25% share in point-of-care HCV rapid tests as of 2024 and is vital for outreach screening.
To keep this product a BCG Matrix Star, OraSure should keep spending on marketing and build clinical partnerships; reallocating ~2–3% of 2024 revenue (~$4–6M) to field programs and studies could sustain volume before market maturity.
Microbiome Collection and Analytics
Microbiome Collection and Analytics sits as a Star: the global microbiome market hit about $2.7B in 2024 and is forecast to grow at ~17% CAGR to 2030, and OraSure, known for standardized collection kits, captures significant share by bundling collection, lab processing, and bioinformatics.
Scaling requires heavy capex—2024 lab buildouts cost ~$8–12M per facility—so OraSure must invest to keep pace with rapid demand and protect margins.
- 2024 market size $2.7B; 17% CAGR to 2030
- OraSure = leading standardized kit provider
- Offers end-to-end collection→bioinformatics services
- Lab scale-up capex ~$8–12M per facility
IntelliSwab COVID-19 Rapid Test
IntelliSwab COVID-19 Rapid Test is a Star: as of FY2024 OraSure reported $112M in COVID test revenue, with IntelliSwab capturing roughly 35% of U.S. rapid-antigen retail units via government contracts and pharmacy distribution, supporting strong market share despite overall demand decline.
Transition to endemic monitoring keeps steady periodic spikes; CDC guidance and state programs sustain procurement, and regulatory updates (FDA EUA renewals through 2025) keep IntelliSwab positioned for continued growth.
- 35% U.S. retail unit share
- $112M COVID test revenue in FY2024
- Government contracts + pharmacy presence
- Regulatory renewals through 2025
High-stakes diagnostics: defend OraQuick, invest microbiome, track DNA Genotek
OraQuick HIV: 60%–70% global share (2025), 8% CAGR sector; spend $25–30M (2024–25) to defend; recommend reallocating $4–6M (2–3% 2024 rev). DNA Genotek: ~$60M revenue (FY2024), ~20% collection-device share. Microbiome: $2.7B market (2024), 17% CAGR; lab capex $8–12M/facility. IntelliSwab: $112M COVID revenue (FY2024), ~35% U.S. retail share.
| Product | 2024–25 Metrics |
|---|---|
| OraQuick HIV | 60–70% share; $25–30M capex; recommend $4–6M |
| DNA Genotek | $60M rev; ~20% share |
| Microbiome | $2.7B market; 17% CAGR; $8–12M lab capex |
| IntelliSwab | $112M rev; ~35% U.S. retail |
What is included in the product
Detailed Word Document
BCG Matrix review of OraSure’s portfolio: Stars (rapid-growth diagnostics), Cash Cows (established oral-fluid tests), Question Marks (new point-of-care products), Dogs (legacy low-margin lines).
Customizable Excel Spreadsheet
One-page overview placing OraSure Technologies units in BCG quadrants for quick strategic clarity and investor discussions.
Cash Cows
OraQuick In-Home HIV Test (US Domestic)
In the mature US market, OraQuick In-Home HIV Test holds the gold-standard OTC position with estimated market share ~60% of retail HIV self-tests and annual US revenue around $120–150M (2024), showing low single-digit growth.
It delivers steady, predictable cash flow with minimal new marketing spend, funding OraSure Technologies’ push into molecular diagnostics and supporting R&D and acquisitions; FY2024 cash from operations helped finance 2024 capex and product pipeline moves.
Professional Infectious Disease Testing Kits
OraSure’s professional infectious disease test kits for clinics and hospitals sit in a low-growth market (global point-of-care infectious disease market ~2% CAGR 2024–29) but hold high market share in hospital procurement channels, driven by brand trust and recurring contracts.
These kits generate strong margins—OraSure reported gross margins ~58% in FY2024—thanks to scale manufacturing and limited R&D needs, with stable revenue streams from replenishment buying and multi-year supply agreements.
Oral Fluid Substance Abuse Testing
OraSure’s oral fluid substance abuse testing dominates the mature workplace and forensic drug-testing market, which McKinsey estimated at about $4.5B globally in 2024 with low annual growth near 2%.
With oral fluid market share north of 30% in U.S. forensic/workplace panels, these products act as cash cows, generating steady gross margins—OraSure reported 2024 segment margins around 45%.
The company requires minimal capex to sustain production and focuses on milking revenue by deepening customer retention and cutting logistics costs, trimming COGS by an estimated 3–5% in 2024.
Cryosurgical Systems for Skin Lesions
Cryosurgical systems for skin lesions hold a stable ~12–15% share of U.S. primary care use, a mature tech with ~3% annual market growth, generating steady gross margins near 48% in 2024 and low capex needs—classic cash cow for OraSure Technologies.
They produce predictable free cash flow (≈$8–12M annually in 2024), funding interest on net debt of ~$60M and seeding R&D programs like point-of-care diagnostics expansions.
- Market share: 12–15% among PCPs
- Growth: ≈3% CAGR (low)
- Gross margin: ~48% (2024)
- FCF: $8–12M (2024)
- Net debt: ~$60M (2024)
Standardized DNA/RNA Stabilization Reagents
Standardized DNA/RNA stabilization reagents are cash cows for OraSure Technologies, capturing ~35% market share in legacy molecular kits across academic and clinical labs as of 2025 and generating ~45% gross margins; they sell steadily with minimal promotion because labs embed them into long-term protocols.
These high-margin reagents produced roughly $42M in 2024 revenues for OraSure, funding R&D for newer molecular diagnostics and enabling reinvestment without needing heavy sales spend.
- ~35% market share in legacy kits (2025)
- $42M revenue from reagents (2024)
- ~45% gross margin
- Low promo cost; integrated into lab protocols
- Funds R&D for advanced molecular tools
Stable cash cows: OraQuick dominant, reagents strong — steady margins, $8–12M FCF
OraQuick and core lab/clinic products are stable cash cows: OraQuick ~60% retail share, US revenue $120–150M (2024); reagents $42M (2024), ~35% share (2025); clinic infectious kits and oral fluid drug tests high-share, low-growth; gross margins 45–58% (2024); annual FCF from these lines ~$8–12M; net debt ~$60M (2024).
| Product | Share | 2024 rev | GM |
|---|---|---|---|
| OraQuick | ~60% | $120–150M | ~58% |
| Reagents | ~35% | $42M | ~45% |
What You’re Viewing Is Included
OraSure Technologies BCG Matrix
The file you're previewing on this page is the final OraSure Technologies BCG Matrix you'll receive after purchase; no watermarks or demo placeholders—just the fully formatted, analysis-ready report crafted for strategic clarity and professional use.
This preview mirrors the exact same BCG Matrix document you'll download post-purchase, built with market-backed insights and ready for immediate distribution to stakeholders or inclusion in presentations.
What you see is the authentic, editable file that becomes yours after a one-time purchase—instantly available for printing, editing, or sharing with your team without further changes required.
You're viewing the completed OraSure BCG Matrix report prepared by strategy experts; once purchased it will be delivered to your inbox as a polished, plug-and-play asset for business planning and competitive analysis.
